[go: up one dir, main page]

UY36742A - Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona - Google Patents

Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona

Info

Publication number
UY36742A
UY36742A UY0001036742A UY36742A UY36742A UY 36742 A UY36742 A UY 36742A UY 0001036742 A UY0001036742 A UY 0001036742A UY 36742 A UY36742 A UY 36742A UY 36742 A UY36742 A UY 36742A
Authority
UY
Uruguay
Prior art keywords
treatment
hsdd
trazodone
bupropion
methods
Prior art date
Application number
UY0001036742A
Other languages
English (en)
Inventor
Clayton Anita
Derogatis Leonard
Katz Molly
Meston Cindy
Robert E Pyke
Robert Taylor Segraves
Nick G Sitchon
Original Assignee
S1 Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57758862&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36742(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by S1 Biopharma Inc filed Critical S1 Biopharma Inc
Publication of UY36742A publication Critical patent/UY36742A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a métodos de tratamiento de mujeres para el Trastorno del Deseo Sexual Hipoactivo (HSDD) con tratamientos diarios orales de combinaciones de bajas dosis y altas dosis de trazodona y bupropión.
UY0001036742A 2016-06-17 2016-06-20 Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona UY36742A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662351904P 2016-06-17 2016-06-17

Publications (1)

Publication Number Publication Date
UY36742A true UY36742A (es) 2016-12-30

Family

ID=57758862

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036742A UY36742A (es) 2016-06-17 2016-06-20 Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona

Country Status (9)

Country Link
KR (1) KR20170142797A (es)
AR (2) AR105087A1 (es)
AU (1) AU2016204151A1 (es)
CA (1) CA2933921A1 (es)
CL (1) CL2016001597A1 (es)
MX (1) MX2016008272A (es)
PE (1) PE20180023A1 (es)
UY (1) UY36742A (es)
WO (1) WO2017218018A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5897864A (en) * 1996-05-23 1999-04-27 Cohen; Alan J. Method for treating sexual dysfunction disorders with compositions containing ginkgo biloba
HUP0202719A3 (en) * 2001-08-21 2006-01-30 Pfizer Prod Inc Pharmaceutical compositions for the treatment of female sexual dysfunctions
BRPI0510074A (pt) * 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
US20070225279A1 (en) * 2006-03-24 2007-09-27 Wyeth Therapeutic combinations for the treatment of depression
US9517254B2 (en) * 2012-08-06 2016-12-13 S1 Biopharma, Inc. Treatment regimens

Also Published As

Publication number Publication date
MX2016008272A (es) 2017-12-18
AR105047A1 (es) 2017-08-30
AU2016204151A1 (en) 2018-01-18
WO2017218018A1 (en) 2017-12-21
AR105087A1 (es) 2017-09-06
KR20170142797A (ko) 2017-12-28
CA2933921A1 (en) 2017-12-17
CL2016001597A1 (es) 2017-10-06
PE20180023A1 (es) 2018-01-09

Similar Documents

Publication Publication Date Title
CO2020010956A2 (es) Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
MX394062B (es) Métodos para el tratamiento del cáncer ovárico.
MX2016006356A (es) Metodos de tratamiento de una tauopatia.
MX2015010312A (es) Metodos para tratamiento del melanoma.
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
MX381069B (es) Profármacos de carbidopa y l-dopa y métodos de uso.
ES2765949T8 (es) Terapia que involucra anticuerpos contra la claudina 18.2 para el tratamiento del cáncer
MX2020009602A (es) Formulaciones de pulverizacion de epinefrina.
CR20160308A (es) Combinaciones de inhibidores de histona deacetilasa y farmacos inmunomoduladores
MX393612B (es) Vacuna contra viruela para tratamiento del cancer.
CL2021001256A1 (es) Vacunación con el dominio alfa 3 de mica/b para el tratamiento del cáncer (divisional sol 201801470)
SA519410324B1 (ar) صياغات رش إيبينيفرين
MX2016010085A (es) Metodos para tratar lesion del cerebro leve.
MX2018012230A (es) Métodos para tratar enfermedades oculares.
MX2017005064A (es) Metodos para tratar afecciones oculares.
MX2017002796A (es) Tasimelteon para tratar el sindrome de smith-magenis.
MX2018013432A (es) Metodo para tratar cancer urotelial del tracto inferior.
CR20150640S (es) Aparato para peinar el cabello
MX2016002307A (es) Tratamiento para el cancer.
MX2016002308A (es) Tratamiento del mieloma multiple.
UY36742A (es) Métodos para el tratamiento de mujeres con trastorno del deseo sexual hipoactivo (hsdd) con tratamiento de combinación de bupropión y trazodona
MX2016016118A (es) Métodos de tratamiento de enfermedades y trastornos del neurodesarrollo.
MX2019006143A (es) Metodos de administracion de tratamiento antifibrotico.
MX387201B (es) Composiciones para el tratamiento contra infecciones.

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20221129